A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents.

  title={A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents.},
  author={Kevin M. Gray and Matthew J. Carpenter and Nathaniel L. Baker and Stacia M DeSantis and Elisabeth Kryway and Karen J. Hartwell and Aimee L. McRae‐Clark and Kathleen T. Brady},
  journal={The American journal of psychiatry},
  volume={169 8},
OBJECTIVE Preclinical findings suggest that the over-the-counter supplement N-acetylcysteine (NAC), via glutamate modulation in the nucleus accumbens, holds promise as a pharmacotherapy for substance dependence. The authors investigated NAC as a novel cannabis cessation treatment in adolescents, a vulnerable group for whom existing treatments have shown limited efficacy. METHOD In an 8-week double-blind randomized placebo-controlled trial, treatment-seeking cannabis-dependent adolescents… 

A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.

A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence.

There was some evidence NAC prevented return to cocaine use in individuals who had already achieved abstinence from cocaine, and N-acetylcysteine may be useful as a relapse prevention agent in abstinent cocaine-dependent individuals.

Alcohol use during a trial of N-acetylcysteine for adolescent marijuana cessation.

An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers

Preliminary data provide the first demonstration of safety and feasibility of the co-administration of NAC and VAR in cigarette smokers, and support future efficacy research on N-acetylcysteine and Var for smoking cessation.

A Double-Blind Randomized Controlled Pilot Trial of N-Acetylcysteine in Veterans with PTSD and Substance Use Disorders

Objective—The antioxidant N-Acetylcysteine (NAC) is being increasingly investigated as a therapeutic agent in the treatment of substance use disorders. Preclinical and clinical findings suggest that

Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.

Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder

Depression may be a risk factor for poor CUD treatment outcome and therefore should be addressed in the context of treatment, but results do not support the use of NAC to concurrently treat co-occurring depressive symptoms and CUD in adults.



N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study.

The purpose of this open-label study was to gather tolerability and preliminary efficacy data for NAC in the treatment of cannabis dependence in young people, and to implicate NAC as a potential treatment for addictive disorders, including cannabis dependence.

Is cocaine desire reduced by N-acetylcysteine?

The inhibition of cocaine cue reactivity is consistent with existing preclinical data and supports the use of N-acetylcysteine as a treatment for cocaine dependence.

Bupropion SR and contingency management for adolescent smoking cessation.

N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action.

N-acetylcysteine has shown promising results in populations with these disorders, including those in whom treatment efficacy has previously been limited, and the therapeutic potential of this acetylated amino acid is beginning to emerge in the field of psychiatric research.

Evidence-Based Psychosocial Treatments for Adolescent Substance Abuse

  • H. WaldronC. Turner
  • Psychology
    Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53
  • 2008
A number of other models are probably efficacious, and none of the treatment approaches appeared to be clearly superior to any others in terms of treatment effectiveness for adolescent substance abuse.

Do Placebo Response Rates from Cessation Trials Inform on Strength of Addictions?

An overview of systematic reviews and meta-analyses of cessation trials, using randomised or quasi-randomised trials and reporting objectively-measured abstinence indicates that nicotine is more difficult to give up than alcohol, cocaine, and opioids.